Anti hypertensive medications and blood sugar: Theories and implications

被引:27
作者
Blackburn, DF
Wilson, TW
机构
[1] Univ Saskatchewan, Coll Pharm & Nutr, Saskatoon, SK S7N 5C9, Canada
[2] Univ Saskatchewan, Coll Med, Saskatoon, SK S7N 5C9, Canada
关键词
diabetes mellitus; hypertension;
D O I
10.1016/S0828-282X(06)70902-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Increased rates (if diabetes have been reported with thiazide diuretics and beta-blockers, but not with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers or calcium channel blockers. These observations are important because significant glycemic effects of drugsmay be a source of accelerated cardiovascular risk that is not detectable during restricted clinical trial follow-up periods. The extent to Which diabetes is affected by these medications remains unclear, as is the precise mechanism by which diabetes is promoted. However, several plausible theories are presented herein. Although drug-induced diabetes has been a concern for several years, not enough is information is available to influence prescribing for the majority of patients. The number one priority should be controlling blood pressure in a timely manner.
引用
收藏
页码:229 / 233
页数:5
相关论文
共 52 条
[1]  
*ALLHAT OFF COORD, 2002, JAMA-J AM MED ASSOC, V288, P2981, DOI DOI 10.1001/JAMA.288.23.2981
[2]  
*AM ASS CLIN END, 2002, ENDOCR PRACT S1, P40
[3]   Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension - A randomized controlled trial [J].
Bakris, GL ;
Fonseca, V ;
Katholi, RE ;
McGill, JB ;
Messerli, FH ;
Phillips, RA ;
Raskin, P ;
Wright, JT ;
Oakes, R ;
Lukas, MA ;
Anderson, KM ;
Bell, DSH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (18) :2227-2236
[4]   Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial [J].
Black, HR ;
Elliott, WJ ;
Grandits, G ;
Grambsch, P ;
Lucente, T ;
White, WB ;
Neaton, JD ;
Grimm, RH ;
Hansson, L ;
Lacourcière, Y ;
Muller, J ;
Sleight, P ;
Weber, MA ;
Williams, G ;
Wittes, J ;
Zanchetti, A ;
Anders, RJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (16) :2073-2082
[5]  
Brown MJ, 2000, LANCET, V356, P514
[6]   Drug-induced disorders of glucose metabolism - Mechanisms and management [J].
Chan, JCN ;
Cockram, CS ;
Critchley, JAJH .
DRUG SAFETY, 1996, 15 (02) :135-157
[7]   Acarbose for prevention of type 2 diabetes mellitus: the STOPNIDDM randomised trial [J].
Chiasson, JL ;
Josse, RG ;
Gomis, R ;
Hanefeld, M ;
Karasik, A ;
Laakso, M .
LANCET, 2002, 359 (9323) :2072-2077
[8]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]   MORBIDITY AND MORTALITY IN THE SWEDISH TRIAL IN OLD PATIENTS WITH HYPERTENSION (STOP-HYPERTENSION) [J].
DAHLOF, B ;
LINDHOLM, LH ;
HANSSON, L ;
SCHERSTEN, B ;
EKBOM, T ;
WESTER, PO .
LANCET, 1991, 338 (8778) :1281-1285